According to previous studies and our data, we speculate that HER2-HER3 co-expression enhances the phosphorylation of Akt and mTOR, decreasing OS in GC patients through a p-mTOR-dependent signaling pathway. This evidence concerns the gene AKT1 and gastric cancer.